Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.780
-0.070 (-3.78%)
At close: Aug 15, 2025, 4:00 PM
1.760
-0.020 (-1.12%)
After-hours: Aug 15, 2025, 7:55 PM EDT
Autolus Therapeutics Employees
As of December 31, 2024, Autolus Therapeutics had 650 total employees, including 647 full-time and 3 part-time employees. The number of employees increased by 179 or 38.00% compared to the previous year.
Employees
650
Change (1Y)
179
Growth (1Y)
38.00%
Revenue / Employee
$46,052
Profits / Employee
-$350,432
Market Cap
473.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 650 | 179 | 38.00% |
| Dec 31, 2023 | 471 | 67 | 16.58% |
| Dec 31, 2022 | 404 | 77 | 23.55% |
| Dec 31, 2021 | 327 | -57 | -14.84% |
| Dec 31, 2020 | 384 | 92 | 31.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AUTL News
- 3 days ago - Autolus Therapeutics: Expanding The Reach Of Its CD19 Therapy, But Still Far From Profitable - Seeking Alpha
- 3 days ago - Autolus Therapeutics plc (AUTL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 23 days ago - Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 - GlobeNewsWire
- 26 days ago - Autolus Therapeutics' CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress - GlobeNewsWire
- 2 months ago - Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market - Seeking Alpha